Xin Lang Cai Jing·2025-09-04 02:44Company Overview - WuXi AppTec, established on December 1, 2000, is located in Shanghai and Hong Kong, and was listed on May 8, 2018. The company provides a comprehensive platform for the discovery, development, and manufacturing of small molecule drugs, serving global pharmaceutical companies [1] - The company's revenue composition is as follows: Chemical business 78.37%, Testing business 12.93%, Biological business 6.02%, Other (supplementary) 1.90%, Other business 0.79% [1] Stock Performance - On September 4, WuXi AppTec's stock fell by 5.04%, trading at 105.29 CNY per share, with a total transaction volume of 4.619 billion CNY and a turnover rate of 1.74%. The total market capitalization is 310.764 billion CNY [1] Fund Holdings - TaiKang Fund has a significant position in WuXi AppTec, with its Medical Health fund (159760) reducing its holdings by 10,200 shares in the second quarter, now holding 121,100 shares, which constitutes 10.52% of the fund's net value, making it the largest holding [2] - The Medical Health fund was established on December 6, 2021, with a latest scale of 80.0606 million CNY. Year-to-date returns are 22.55%, ranking 1802 out of 4222 in its category, while the one-year return is 37.42%, ranking 2442 out of 3789 [2]